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Abstract: The worldwide burden of snakebite is high and venomous snakes are found in many regions 
of the world and are a threat to public health. In Italy, for instance, viper bites are an infrequent but not 
negligible event. Although people who have been bitten by a snake rarely wish to donate blood within a “short” 
time, it is however important to evaluate their eligibility to donate blood or blood components as their 
donation could be a problem for donor management, especially if a specific policy is not in place. The aim of 
this manuscript is to summarise the worldwide existing donor deferral policy for snakebites and to provide 
some indications in order to facilitate decision-making and to guarantee maximum safety for the donors as 
well as for the recipients.
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Introduction
The worldwide burden of snakebite is high. In fact, 
venomous snakes are found in many regions of the world 
and are a threat to public health, especially in the rural 
tropics where they are most abundant. Out of more than 
3,000 species of snakes in the world, about 600 are venomous 
and over 200 are considered to be clinically significant (1). 
Annually, snakebites cause about 125,000 deaths and the 
permanent disabling or disfiguring of 400,000 people, mainly 
in developing countries (2-4). The individuals affected are 
mostly women, children and agricultural workers in poor 
rural communities (2). In the World Health Organization 
(WHO) database and image library, species of venomous 
snakes are listed in two categories according to the degree of 
public health risk that they present (1):
(I) Category 1 (highest medical importance): highly 
venomous snakes that are common or widespread 
and cause numerous snakebites, resulting in high 
levels of morbidity, disability or mortality; 
(II) Category 2 (secondary medical importance): highly 
venomous snakes capable of causing morbidity, 
disability or death, for which exact epidemiological 
or clinical data may be lacking; and/or are less 
frequently implicated (due to their activity cycles, 
behaviour, habitat preferences or occurrence in areas 
remote to large human populations).
In Italy, viper bites are an infrequent event, though 
envenomation can cause severe complications, especially in 
children, related to their dose/body size ratio. Four species 
of poisonous snakes are present in Italy (1): the common 
viper (Vipera aspis), common throughout the country; the 
Vipera berus, found mainly in the Alps; the Vipera ammodydes 
found in the mountainous and hilly regions of North-East 
Italy; the Vipera ursini, found in the mountains of Central 
Italy, whose bite is never fatal (Table 1). 
Blood Transfusion Services (BTS) have the responsibility 
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to collect blood only from donors who are at low risk for 
any infection that could be transmitted through transfusion 
and who are unlikely to jeopardize their own health by 
blood donation. A rigorous process to assess the suitability 
of prospective donors is therefore essential to protect the 
safety and sufficiency of the blood supply, and safeguard 
the health of recipients of transfusion and blood donors 
themselves, while ensuring that suitable donors are not 
deferred unnecessarily. Persons disqualified from donating 
blood are known as “deferred” donors. A prospective donor 
may be deferred at any point during the “blood donor 
selection process”. A person can be deferred temporarily for 
a condition that is usually reversible, or permanently if he/
she suffers from a certain medical condition (5). 
Although people who have been bitten by a snake rarely 
wish to donate blood within a “short” time, it is however 
important to evaluate their eligibility to donate blood or 
blood components as their donation could be a problem 
for donor management, especially if a specific policy is not 
in place. 
The aim of this manuscript is to summarise the 
worldwide existing donor deferral policy for snakebites and 
to provide some indications in order to facilitate decision-
making and to guarantee maximum safety for the donors as 
well as for the recipients.
Snakebite effects on the human body
Snakebites often result in two puncture wounds from the 
reptile’s fangs. While most snakebites are innocuous as they 
are caused by non-poisonous species, sometimes poisoning 
does occur when venomous species are involved (6). 
A dry bite is a “venomous snake bite without envenoming”, 
in which no venom is released. At least 25% of snakebite 
cases can be dry bites. Dry bites can occur from all venomous 
snakes, but their frequency varies from species to species (6). 
The function of venomous snakebites is to immobilise 
the prey and to facilitate its digestion (7). The toxic 
component of snake venom can be classified into four broad 
categories: enzymes, polypeptides, glycoproteins, and low 
molecular weight compounds. They can also be classified as 
protein (90–95%) and non-protein (5–10%) compounds (7). 
Snake venom can be classified into haemotoxic, neurotoxic, 
necrotoxic, cardiotoxic, and nephrotoxic since snake venom 
has different predominant effects depending on the family 
(e.g., the venom of Crotalidae and Viperidae snakes is more 
haemotoxic and necrotoxic, whereas venom of the Elapidae 
subfamily is mainly neurotoxic) (8). 
Snakebites have a wide range of effects, which go from 
simple puncture wounds to life-threatening illness and death 
(9-12). As far as venomous snakes concerned, the degree of 
intoxication and symptoms vary greatly: (I) no intoxication 
(“dry” bite); (II) mild intoxication (local oedema and pain); 
(III) moderate intoxication (pain, oedema spreading out 
from the bite zone, and systemic signs); and (IV) severe 
intoxication (shock, severe coagulopathy, and massive 
oedema) (10). The severity and outcome of a snakebite 
depend on the following factors: (I) bite localization; (II) 
snake’s size, condition of glands and teeth, bite angle, and 
bite duration; (III) microflora of the snake’s mouth and 
patient’s skin; (IV) patient’s age, weight, and state of health; 
(V) patient’s activity after a bite that influences the spread 
of the venom. Snake venom causes local and systemic body 
reactions (10).
Local signs are puncture wounds inflicted by the snake’s 
fangs; there can be one, two, or in rare cases more than 
two (9-12). The wound oozes with sero-haemorrhagic fluid 
and non-coagulant blood. Local oedema typically develops 
in a few to a maximum of 30 minutes. The skin becomes 
red and painful; this depends on the species of the snake in 
question. The venom of Viperidae snakes is characterized by 
a dominating cytotoxic effect; therefore, the pain is severe 
and burning. Petechiae, ecchymoses, and in rare cases 
vesicles as well as local tissue necrosis appear rapidly. 
Systemic signs and symptoms are generalized, mainly 
haematologic and neuromuscular (9-12). General symptoms 
are weakness, fatigue, anxiety, tachycardia, weak pulse, 
bradycardia, tachypnea, sweating, nausea and vomiting, 
diarrhoea and acute abdominal pain, hypothermia or 
chills and fever, regional lymphadenopathy, lymphangitis 
(developing in 1–2 days), metal taste in mouth, headache, 
thirst, pulmonary oedema, heart failure, hypotension, 
collapse, shock, cerebral anoxia (sleepiness, slurred speech, 
disorientation, delirium, loss of consciousness), and 
anaphylactic reaction to venom proteins (facial, tongue, 
Table 1 Species of poisonous snakes present in Italy
Common name Species name Category*
Nose-horned viper Vipera ammodytes 2
Asp viper Vipera aspis 1
European adder Vipera berus 2
Meadow viper Vipera ursinii 2
*, risk category according to WHO (1).
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and epiglottic angioedema, which causes respiratory tract 
obstruction). If hypotension rapidly develops, it is one of 
the main signs of intoxication. If present, renal damage 
manifests as proteinuria, haemoglobinuria, myoglobinuria, 
azotemia, and anuria. A convulsive syndrome may 
occur due to cerebral anoxia caused by hypotension and 
anaemia, and not due to direct venom neurotoxicity. 
An electrocardiogram (ECG) may show nonspecific 
changes of the ST segment and the T wave, and episodes 
of atrial fibrillation. Haematological changes appear as 
coagulopathy and haemorrhagic syndrome ranging from 
local bleeding to profuse blood loss: bleeding from gums 
and nose, haematemesis, melena, haematuria, petechiae, 
and ecchymoses in the snakebite area. Bleeding may occur 
from the kidneys, lungs, peritoneum, rectum, vagina, 
endometrium, and pathological sites such as peptic ulcers. 
There might be a slightly noticeable icterus. Laboratory 
tests show prolonged prothrombin and activated partial 
thromboplastin time (APTT), decreased fibrinogen, 
plasminogen, factor XIII, factor V, antithrombin III, 
protein C levels, thrombocytopenia, elevated D-dimer level, 
morphological erythrocyte changes and anaemia, as well as 
neutrophilic leucocytosis. Neuromuscular damage manifests 
as paresthesias in the perioral region and fingers, muscular 
fasciculations, spasms, weakness, diplopia, hypersalivation, 
ptosis, myosis, dysphonia, dysphagia, trismus, respiratory 
dysfunction, and paralysis. The main reasons for death 
are shock, intracranial haemorrhage in the hypophysis, 
alimentary tract haemorrhage, and renal tubular necrosis.
As soon as the patient reaches hospital it is important 
to assess circulation, airway and breathing (CAB) before 
starting any kind of treatment, this includes appropriate 
management of any active bleeding and of the airway to 
avoid respiratory failure or aspiration (12,13). Monitoring of 
vital signs can be useful to forecast complications (13). After 
these measures have been taken care of, hydration through 
the use of a saline solution or Ringer’s lactate solution is 
necessary, as snake venom is capable of moving intravascular 
fluid to the “interstitial space”. Laboratory tests that are 
useful in these settings are complete blood count (CBC), 
prothrombin time (PT)/partial thromboplastin time (PTT), 
serum electrolytes, creatinine phosphokinase (CPK), 
urinalysis, blood urea nitrogen (BUN) and creatinine and a 
cross-match for blood. The wound should be inspected. The 
most important decision in managing a case of snakebite 
is to decide whether to administer an antivenomous serum 
or not (12). An antivenom is the mainstay of treatment of 
snakebite envenoming. However, adverse reactions to the 
antivenoms that are available are common in many parts of 
the world where snakebites are frequent (14).
A tetanus prophylaxis should be administered as the spores 
of the bacteria Clostridium tetani might enter the body when 
the snake bites. An antibiotic prophylaxis should not be 
administered, unless it is known that an incision of the bite 
has been performed or the poison has been sucked out of the 
wound. In these cases, a broad-spectrum antibiotic can be 
given. If the wound becomes infected, antibiotics are given 
according to the flora cultured from the wound’s secretions; 
in 90% of cases, Enterobacter spp., Pseudomonas spp., and 
Clostridium perfringens (9-13) are found. 
For symptomatic treatment, antiemetic and antihistaminic 
drugs are given; following haemorrhage, fresh plasma, 
cryoprecipitate, and platelet mass are used; hypotension is 
corrected by crystalloids and vasopressors; pain is relieved 
by nonsteroidal anti-inflammatory drugs; and muscle 
spasms or seizures are treated with calcium gluconate. 
The policies
Blood donor selection criteria is in place to ensure that only 
blood donors who meet the criteria are eligible to donate blood. 
An individual who does not meet the blood donor selection 
criteria will be deferred from blood donation (5,15-17). 
Blood donation deferral is a precautionary measure taken 
to protect the blood donor during the blood donation 
process as well as the patient who receives the transfusion. 
The period of deferral depends on the specific reason for 
disqualification (5,15-19). There are two types of deferral: 
(I) temporary deferral or (II) permanent deferral (5). An 
individual clinical and anamnestic evaluation is performed 
in the pre-donation phase. 
For a donor who wishes to donate blood or blood components 
after being bitten by a snake, some recommendations stating 
the recommended deferral period for deferred donors 
have been provided by international or national health 
authorities (Table 2). 
In 2009, in its publication “Safe blood and blood products. 
Module 1: safe blood donation”, the WHO stated that a person 
may be accepted as donors after recovering from a snakebite 
(minimum 6 months) (20).
The Joint Professional Advisory committee (JPAC) of 
the United Kingdom Blood Transfusion Services (UKBTS) 
in the “Whole blood and component donor selection guidelines 
(WB&C-DSG)” stated that donors must not donate until 
fully recovered and that in the donor evaluation the deferral 
period for surgery, transfusions or wounds, mouth and skin 
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ulcers must be taken into account (21).
The Malaysia National Blood Centre, Ministry of 
Health in “Transfusion practice guidelines for clinical 
and laboratory personnel” recommended a deferral of 
3 months after recovery from snakebite (22). 
Moreover, also the Egyptian National Blood Transfusion 
Services indicated a deferral period of 3 months (23).
According to the Japanese Red Cross, anyone who has been 
given an antiserum for tetanus, snakebite or other poisons, etc. 
within the past 3 months may not donate blood (24). 
Discussion 
As reported in Indian studies, snakebites are the cause of 
0.2% (25) to 0.481% (26) of temporary deferrals (3 months).
In Italy, an estimation of the total number of snakebites 
per year ranges from 565 to 2,247 (3,27,28). Most subjects 
(about 60%) do not show any symptomatology related to 
envenomation (27).
From our research, it emerged that at national level 
there is a lack of regulations/guidelines regarding the 
management of candidate donors following a snakebite.
Considering the available information, at least a 3-month 
deferral after the snakebite event is suggested and anyway 
not until full recovery. Furthermore, the decision should 
take into account several factors: the type of snake involved 
(venomous or not), the characteristics of the injury, the 
characteristics of the venom (if released by the snake), 
the symptoms (local or systemic), and the treatment/s 
performed (surgery, transfusion therapy, supportive therapy, 
antibiotic therapy, etc.). 
For example, in Italy, a Ministerial Decree of November 
2nd, 2015 states that (29):
(I) Donors with a history of anaphylaxis are deferred 
permanently; 
(II) Donors with acquired coagulopathy are deferred 
permanently;
(III) Donors who have been vaccinated for rabies (after 
exposure) are deferred for 1 year;
(IV) Recipients of blood and blood products are 
deferred for 4 months following transfusion;
(V) Donors after undergoing major surgery are 
deferred for 4 months; 
(VI) Donors with a history of severe allergic reaction 
(excluding history of anaphylaxis) due to exposure 
to substances or drugs (especially penicillin, 
cepha lospor in  or  in sec t  venom f rom the 
Hymenoptera order) are deferred for 2 months from 
the last exposure; 
(VII) Donors with a history of recent assumption of drugs 
(including antibiotics) are subject to temporary 
deferral for a variable period of time depending 
on the active principle of prescribed drugs, the 
pharmacokinetics and the treated disease. For people 
taking medicines with a proven teratogenic effect, 
the suspension should be extended for an appropriate 
period in relation to the pharmacokinetic properties 
of the drug in question.
In addition, attention must be given to the laboratory 
tests in order to exclude the presence of coagulopathies 
and/or abnormalities, especially of a haematological nature. 
When the deferral period has expired, in order to assess 
donor eligibility, an evaluation of haemoglobin levels, 
white blood cells (WBCs), platelet count, electrolytes panel 
(sodium, potassium, chloride, bicarbonate) urea, creatinine, 
calcium, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), total proteins, albumin, CPK, PT, 
PTT, antithrombin (AT) levels, and fibrinogen should be 
performed.
Conclusions
In Table 3, the most useful questions in the event of 
snakebite are reported.
Table 2 International policies
Authority A subject may be accepted as a donor
WHO (20) After recovery (minimum 6 months)
United Kingdom (21) After full recovery 
Malaysia National Blood Centre (22) After recovery (minimum 3 months)
Egyptian National Blood Transfusion Services (23) After recovery (minimum 3 months)
Japanese Red Cross (24) If he/she has not been given an antiserum for tetanus or received a 
snakebite or other poisons within the past 3 months
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Although people who have been bitten by a snake rarely 
wish to donate blood within a “short” time, it is however 
important to evaluate their eligibility to donate blood or 
blood components as their donation could be a problem 
for donor management. Considering that the assessment 
of donor suitability for blood donation must stem from 
an individual risk assessment, some indications should be 
provided:
(I) The donor without intoxication (“dry” bite) or with 
mild intoxication (local oedema and pain), without 
any systemic, allergic or haemorrhagic symptom, 
without assumption of drugs or vaccination related 
to the snakebite episode should be deferred at least 
for 3 months;
(II) The donor with moderate intoxication (pain, 
oedema spreading out of the bite zone, and 
systemic signs) or severe intoxication (shock, severe 
coagulopathy, and massive oedemas) without a 
history of anaphylaxis or acquired coagulopathy 
should be deferred for at least 6 months, or until 
fully recovered; 
(III) The donor with a history of anaphylaxis or acquired 
coagulopathy should be deferred permanently. 
If the Italian legislation is taken into account, the deferral 
period indicated in point (I) and point (II) could be longer (29). 
Moreover, in order to assess donor eligibility, when the 
deferral period has expired, the following tests should be 
performed: WBC count, electrolytes panel, urea, creatinine, 
calcium, ALT, AST, total proteins, albumin, CPK, PT, PTT, 
fibrinogen, and AT.
Unfortunately, no detailed indications on blood donors’ 
deferral after a venomous snakebite have been provided 
by the European/International Health Authorities or by 
Transfusion Medicine Societies. In our opinion, well-
defined and shared guidelines resulting from an expert 
working group would be appropriate to promote best and 
standardised practices in blood transfusion services. This 
would also guarantee maximum safety for both blood 
donors and recipients, as well as a safe, sufficient and timely 
supply of blood and blood products.
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